



# **DENIS CHEM LAB LIMITED**

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

14<sup>th</sup> November, 2022

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

**Company Code No. 537536**

Dear Sirs,

**Sub: Submission of Unaudited Financial Results for the Quarter ended on 30<sup>th</sup> September, 2022**

We refer to our letter dated 3<sup>rd</sup> November, 2022 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2022.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2022 along with Limited Review Report thereon.

The Meeting of Board of Directors was commenced at 10:00 a.m. and concluded at 12:45 p.m.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,  
**for DENIS CHEM LAB LIMITED**

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**DIN: 00087114**



Encl: As above.



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 - ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD - 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30<sup>TH</sup> SEPTEMBER, 2022

(Rs. In lakh)

| Particulars         |   | Quarter ended on |             |             | Half Year ended on<br>(Cumulative) |             | Previous<br>Year ended<br>on |
|---------------------|---|------------------|-------------|-------------|------------------------------------|-------------|------------------------------|
|                     |   | 30-09-2022       | 30-06-2022  | 30-09-2021  | 30-09-2022                         | 30-09-2021  | 31-03-2022                   |
| (Refer Notes Below) |   | (Unaudited)      | (Unaudited) | (Unaudited) | (Unaudited)                        | (Unaudited) | (Audited)                    |
| 1                   | Revenue from operations   | 4450.90          | 3928.72     | 3,176.07    | 8379.62                            | 6,491.82    | 13655.65                     |
| 2                   | Other income  | 10.76            | 7.52        | 1.08        | 18.28                              | 7.81        | 104.59                       |
| 3                   | Total Income (1+2)  | 4461.66          | 3936.24     | 3,177.15    | 8397.90                            | 6,499.63    | 13760.24                     |
| 4                   | Expenses  |                  |             |             |                                    |             |                              |
|                     | a. Cost of Materials consumed   | 1969.37          | 1964.15     | 1,431.97    | 3933.52                            | 2,992.86    | 6831.08                      |
|                     | b. Purchases of stock-in-trade  | 242.53           | 240.68      | 49.59       | 483.21                             | 105.07      | 400.75                       |
|                     | c. Changes in inventories of<br>finished goods, work-in-<br>progress and stock-in-trade | 27.52            | 80.12       | (33.87)     | 107.64                             | 125.66      | 2.58                         |
|                     | d. Employee benefits expense  | 319.05           | 282.94      | 259.76      | 601.99                             | 525.26      | 1173.99                      |
|                     | e. Finance costs  | 8.48             | 17.24       | 20.47       | 25.72                              | 44.08       | 75.64                        |
|                     | f. Depreciation & amortisation<br>expense   | 136.63           | 135.57      | 140.92      | 272.20                             | 280.50      | 575.75                       |
|                     | g. Other expenses   | 1314.77          | 930.28      | 967.35      | 2245.05                            | 1,860.41    | 3821.11                      |
|                     | Total Expenses  | 4018.35          | 3650.98     | 2,836.19    | 7669.33                            | 5,933.84    | 12871.90                     |
| 5                   | Profit before exceptional items<br>and tax (3-4)  | 443.31           | 285.26      | 340.96      | 728.57                             | 565.79      | 888.34                       |
| 6                   | Exceptional items   | -                | -           | -           | -                                  | -           | -                            |
| 7                   | Profit before tax (5+6)   | 443.31           | 285.26      | 340.96      | 728.57                             | 565.79      | 888.34                       |
| 8                   | Tax expense:  |                  |             |             |                                    |             |                              |
|                     | Current tax   | 117.29           | 86.88       | 78.95       | 204.17                             | 139.00      | 215.00                       |
|                     | Deferred tax  | 14.89            | (16.21)     | 11.45       | (1.32)                             | 15.02       | 47.04                        |
| 9                   | Profit for the period from<br>continuing operations (7-8)                               | 311.13           | 214.59      | 250.56      | 525.72                             | 411.77      | 626.30                       |
| 10                  | Profit/ (loss) from<br>discontinuing operations before<br>Tax                           | -                | -           | -           | -                                  | -           | -                            |
| 11                  | Tax expense of discontinuing<br>operations  | -                | -           | -           | -                                  | -           | -                            |
| 12                  | Profit/ (loss) from<br>Discontinuing operations (after<br>tax) (10-11)                  | -                | -           | -           | -                                  | -           | -                            |
| 13                  | Profit for the period (9+12)  | 311.13           | 214.59      | 250.56      | 525.72                             | 411.77      | 626.30                       |







# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS  
[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



| Particulars   | Quarter ended on |             |             | Half Year ended on<br>(Cumulative) |             | Previous<br>Year<br>ended on<br>31-03-<br>2022 |
|---|------------------|-------------|-------------|------------------------------------|-------------|--|
|   | 30-09-2022       | 30-06-2022  | 30-09-2021  | 30-09-2022                         | 30-09-2021  |  |
|   | (Unaudited)      | (Unaudited) | (Unaudited) | (Unaudited)                        | (Unaudited) |  |
| 14 Other Comprehensive Income   |                  |             |             |                                    |             |  |
| <i>Items that will not be reclassified subsequently to profit or loss</i>         |                  |             |             |                                    |             |  |
| Gain/(loss) on Remeasurement of defined benefit plan                              | 3.04             | -           | 5.11        | 3.04                               | 5.11        | (38.16)  |
| Incometax relating to items that will not be reclassified to Profit or loss       | (0.84)           | -           | (1.42)      | (0.84)                             | (1.42)      | 10.62  |
| Income tax relating to items that will not be reclassified to profit or loss      | -                | -           | -           | -                                  | -           | -  |
| <i>Items that will be reclassified subsequently to profit or loss</i>             | -                | -           | -           | -                                  | -           | -  |
| Income tax relating to items that will be reclassified to profit or loss          | -                | -           | -           | -                                  | -           | -  |
| Other Comprehensive Income, net of tax  | 2.20             | -           | 3.69        | 2.20                               | 3.69        | (27.55)  |
| 15 Total Comprehensive Income for the period (13+14)                              | 313.30           | 214.59      | 254.25      | 527.92                             | 415.46      | 598.75   |
| 16 Paid-up equity shares capital (Face Value per share Rs. 10/-)                  | 1387.67          | 1387.67     | 1,387.67    | 1387.67                            | 1,387.67    | 1,387.67                                       |
| 17 Reserves excluding Revaluation Reserves  |                  |             |             |                                    |             | 5257.46  |
| 18 Earnings Per Share of Rs. 10/- each (for continuing operations)                |                  |             |             |                                    |             |  |
| - Basic   | 2.24             | 1.55        | 1.81        | 3.79                               | 2.97        | 4.51   |
| - Diluted   | 2.24             | 1.55        | 1.81        | 3.79                               | 2.97        | 4.51   |
| 19 Earnings Per Share of Rs. 10/- each (for discontinued operations)              |                  |             |             |                                    |             |  |
| - Basic   |                  | -           | -           | -                                  | -           | -  |
| - Diluted   |                  | -           | -           | -                                  | -           | -  |
| 20 Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations) |                  |             |             |                                    |             |  |
| - Basic   | 2.24             | 1.55        | 1.81        | 3.79                               | 2.97        | 4.51   |
| - Diluted   | 2.24             | 1.55        | 1.81        | 3.79                               | 2.97        | 4.51   |







# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



## NOTES:

### 1. STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. In lakh)

| Sr. No. | Particulars                                | As at 30-09-2022<br>(Unaudited) | As at 31-03-2022<br>(Audited) |
|---------|--|---------------------------------|-------------------------------|
|         | <b>ASSETS</b>                              |                                 |                               |
| 1       | <b>Non-Current Assets</b>                  |                                 |                               |
|         | Property, plant and equipment              | 3950.49                         | 4133.24                       |
|         | Capital work-in-progress                   | -                               | -                             |
|         | Investment property                        | -                               | -                             |
|         | Goodwill                                   | -                               | -                             |
|         | Other intangible Assets                    | 30.54                           | 32.79                         |
|         | Intangible Assets under development        | -                               | -                             |
|         | Biological Assets other than bearer plants | -                               | -                             |
|         | Non-Current Financial Assets:              |                                 |                               |
|         | (i) Investments, Non-Current               | -                               | -                             |
|         | (ii) Trade receivables, Non-Current        | -                               | -                             |
|         | (iii) Loans, Non-Current                   | -                               | -                             |
|         | (iv) Other Non-Current financial Assets    | 117.34                          | 97.78                         |
|         | (v) Tax Assets Non- Current                | -                               | 28.78                         |
|         | Deferred tax Assets (net)                  | -                               | -                             |
|         | Other Non-Current Assets                   | 47.40                           | -                             |
|         | <b>Total Non-Current Assets</b>            | <b>4145.77</b>                  | <b>4292.59</b>                |
| 2       | <b>Current Assets</b>                      |                                 |                               |
|         | Inventories                                | 841.35                          | 989.05                        |
|         | Current financial asset:                   |                                 |                               |
|         | (i) Current investments                    |                                 |                               |
|         | (ii) Trade receivables, Current            | 3695.04                         | 3183.72                       |
|         | (iii) Cash and cash equivalents            | 459.66                          | 130.11                        |
|         | (iv) Bank balance other than above         | 807.01                          | 791.72                        |
|         | (v) . Loans, Current                       | -                               | -                             |
|         | (vi) Other Current financial Assets        | 45.57                           | 44.64                         |
|         | Current tax Assets (net)                   | -                               | -                             |
|         | Other Current Assets                       | 252.34                          | 206.99                        |
|         | <b>Total Current Assets</b>                | <b>6100.97</b>                  | <b>5346.23</b>                |
|         | <b>TOTAL ASSETS</b>                        | <b>10246.74</b>                 | <b>9638.82</b>                |







# DENIS CHEM LAB LIMITED


MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



| Sr. No. | Particulars  | As at 30-09-2022<br>(Unaudited) | As at 31-03-2022<br>(Audited) |
|---------|--|---------------------------------|-------------------------------|
|         | <b>EQUITY AND LIABILITIES</b>  |                                 |                               |
| 1       | <b>Equity</b>  |                                 |                               |
|         | Equity share capital   | 1387.67                         | 1,387.67                      |
|         | Other Equity   | 5785.39                         | 5257.46                       |
|         | <b>Total Equity</b>  | <b>7173.06</b>                  | <b>6645.13</b>                |
| 2       | <b>Liabilities</b>   |                                 |                               |
|         | <b>Non-Current Liabilities</b>   |                                 |                               |
|         | Non-Current financial Liabilities:   |                                 |                               |
|         | (i) Borrowings, Non-Current  | 172.95                          | 217.65                        |
|         | (ii) Trade payables, Non-Current   |                                 |                               |
|         | (a) total outstanding dues of micro enterprises and small enterprises                      | -                               | -                             |
|         | (b) total outstanding dues of creditors other than micro enterprises and small enterprises | -                               | -                             |
|         | (iii) Other Non-Current financial Liabilities  | -                               | -                             |
|         | Provisions, Non-Current  | 18.99                           | 59.93                         |
|         | Deferred tax Liabilities (net)   | 252.35                          | 185.57                        |
|         | Other Non-Current Liabilities  |                                 |                               |
|         | <b>Total Non-Current Liabilities</b>   | <b>444.29</b>                   | <b>463.15</b>                 |
|         | <b>Current Liabilities</b>   |                                 |                               |
|         | Current financial Liabilities:   |                                 |                               |
|         | (i) Borrowings, Current  | 101.43                          | 104.11                        |
|         | (ii) Trade payables, Current   |                                 |                               |
|         | (a) total outstanding dues of micro enterprises and small enterprises                      | -                               | -                             |
|         | (b) total outstanding dues of creditors other than micro enterprises and small enterprises | 1763.89                         | 1969.74                       |
|         | (iii) Other Current financial Liabilities  | 571.47                          | 314.27                        |
|         | Other Current Liabilities  | 65.76                           | 63.11                         |
|         | Provisions, Current  | 47.73                           | 44.62                         |
|         | Current tax Liabilities (Net)  | 79.11                           | 34.69                         |
|         | Deferred government grants, current  |                                 | -                             |
|         | <b>Total Current Liabilities</b>   | <b>2629.39</b>                  | <b>2530.54</b>                |
|         | <b>Total Liabilities</b>   | <b>3073.68</b>                  | <b>2993.69</b>                |
|         | <b>TOTAL EQUITY AND LIABILITIES</b>  | <b>10246.74</b>                 | <b>9638.82</b>                |







# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



ISO 9001:2008

## 2. STATEMENT OF CASH FLOWS FOR THE PERIOD FROM 1<sup>ST</sup> APRIL, 2022 TO 30<sup>TH</sup> SEPTEMBER, 2022

(Rs. in Lakh)

| Particulars   | For the period ended<br>30 <sup>th</sup> September, 2022 | For the year ended<br>31 <sup>st</sup> March, 2022 |
|---|--|--|
| <b>(A) Cash flow from operating activities</b>  |  |  |
| Profit before tax   | 728.57   | 888.34   |
| <b>Adjustment for:</b>  |  |  |
| Finance Costs   | 25.72  | 75.64  |
| Depreciation and amortization   | 272.20   | 575.75   |
| Interest received   | (18.28)  | (19.16)  |
| Profit on Sale of Asset   | -  | (3.07)   |
| Reversal of Provision for Expected Credit Loss (ECL)  | -  | -  |
| Unrealized foreign exchange fluctuation (gain)/loss   | -  | -  |
| Remeasurement on defined benefit obligation   | 3.04   | (38.16)  |
| <b>Operating Profit / (Loss) before working capital changes</b>                                   | <b>1011.25</b>   | <b>1479.34</b>                                     |
| <b>Changes in working capital:</b>  |  |  |
| (Increase)/Decrease in Inventories  | 147.70   | (78.40)  |
| (Increase)/Decrease in Trade Receivables  | (511.31)   | 103.89   |
| (Increase)/Decrease in Other Financial Assets   | (20.50)  | 64.16  |
| (Increase)/Decrease in Other Assets   | (45.35)  | (74.85)  |
| Increase/(Decrease) in Trade Payables   | (205.86)   | 402.54   |
| Increase/(Decrease) in Provisions   | (37.82)  | (77.94)  |
| Increase / (Decrease) in Other Current Liabilities  | 2.65   | (24.61)  |
| Increase / (Decrease) in Other Liabilities  | 257.20   | 21.07  |
| <b>Cash generated / (used in) from operations</b>   | <b>597.96</b>  | <b>1815.2</b>                                      |
| Less : Tax Paid (net of refunds, if any)  | (63.72)  | 108.17   |
| <b>Net Cash generated from operating activities (A)</b>   | <b>534.24</b>  | <b>1707.03</b>                                     |
| <b>(B) Cash flow from investing activities</b>  |  |  |
| Capital expenditure on Property, Plant and Equipment, Intangible assets, Capital Work in Progress | (134.58)   | (549.05)   |
| Insurance claim received for fixed assets   | -  | 10.50  |
| Interest received   | 18.28  | 19.16  |
| Bank deposits / margin money withdrawn / (placed) (net)   | (15.29)  | (494.40)   |
| <b>Net Cash used in investing activities (B)</b>  | <b>(131.59)</b>  | <b>(1013.79)</b>                                   |
| <b>(C) Cash flow from financing activities</b>  |  |  |
| Dividend and dividend tax paid  |  | (104.08)   |
| Increase/(Decrease) in Short-term borrowings  | (2.68)   | (407.55)   |
| Increase/(Decrease) in Long-term borrowings   | (44.71)  | (132.83)   |
| Finance Costs Paid  | (25.72)  | (75.64)  |
| <b>Net Cash generated from financing activities (C)</b>   | <b>(73.11)</b>   | <b>(720.09)</b>                                    |
| <b>Net Increase / (Decrease) in cash and cash equivalents (A)+(B)+(C)</b>                         | <b>329.54</b>  | <b>(26.85)</b>                                     |
| <b>Cash and cash equivalents at the beginning of the period/ year</b>                             | <b>130.11</b>  | <b>156.97</b>                                      |
| <b>Cash and cash equivalents at the end of the period / year</b>                                  | <b>459.66</b>  | <b>130.11</b>                                      |







## DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)



|   |  |
|---|--|
| 3 | These financial results were reviewed by the audit committee and thereafter have been approved by the board of directors at its meeting held on Monday, November 14, 2022. The Statutory Auditors have conducted audit of these financial results and issued an unmodified opinion on the same.  |
| 4 | These audited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules as amended from time to time   |
| 5 | The Company is operating only in one segment i.e. manufacturing & sales of transfusion solutions in bottles.   |
| 6 | The Company does not have any subsidiary / associate.  |
| 7 | On September 20, 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Government of India inserted Section 115BAA in the Income Tax Act, 1961 which provides domestic companies a non-reversible option to Pay corporate tax at reduced rates effective April 01, 2019 subject to certain conditions. The Company has made an assessment of the impact of the Taxation Laws (Amendment) Act, 2019 and decided to continue with the existing tax structure until utilization of accumulated Minimum Alternate Tax (MAT) Credit.   |
| 8 | The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020 and has invited suggestions from the stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the said code become effective including related rules framed thereunder to determine the financial impact are published. |
| 9 | Figures for the previous period/year have been regrouped/rearranged to make the same comparable with current period/year figures.  |

Date: 14<sup>th</sup> November, 2022  
Place: Ahmedabad



for DENIS CHEM LAB LIMITED


HIMANSHU C. PATEL  
MANAGING DIRECTOR  
DIN: 00087114



**Independent Auditor's Review Report on quarterly and year to date Unaudited Standalone Financial Results of M/s. DENIS CHEM LAB LIMITED pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

To The Board of Directors of  
**DENIS CHEM LAB LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **DENIS CHEM LAB LIMITED** ("the Company") for the quarter and period of six months ended on September 30, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Statement").
2. This statement which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that figures for the corresponding quarter and six months ended September 30, 2021, for the year ended on March 31, 2022 and for the quarter ended June 30, 2022 are based on the previously issued financial results or annual financial statements that were reviewed/audited by predecessor auditors vide their unmodified report dated 12th November, 2021, 26th May, 2022 and 10th August, 2022 respectively.
5. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : Ahmedabad  
Date : 14<sup>th</sup> November, 2022

**For SHAH & SHAH ASSOCIATES**

Chartered Accountants  
FRN 113742W

*N. C. Tanna*

**VASANT C. TANNA**  
**PARTNER**

Membership Number 100 422  
UDIN22100422BDAATX6369